28 results on '"Baker, Daniel"'
Search Results
2. Obesity and rates of clinical remission and low MRI inflammation in rheumatoid arthritis
3. Relationship of patient-reported outcomes with MRI measures in rheumatoid arthritis
4. Validity of early MRI structural damage end points and potential impact on clinical trial design in rheumatoid arthritis
5. Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1□year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial
6. Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial
7. Greater body mass independently predicts less radiographic progression on X-ray and MRI over 1–2 years
8. Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks
9. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis
10. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis
11. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis
12. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis : results of the GO-FORTH study
13. A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate
14. Relationship of patient-reported outcomes with MRI measures in rheumatoid arthritis
15. Validity of early MRI structural damage end points and potential impact on clinical trial design in rheumatoid arthritis
16. Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial
17. Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial
18. Ankylosing spondylitis patients with and without psoriasis do not differ in disease phenotype
19. MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor
20. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial
21. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study
22. MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis
23. A stratified model for health outcomes in ankylosing spondylitis
24. Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial.
25. Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks.
26. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial.
27. MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis.
28. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.